恩捷股份(002812.SZ):玉溪恩捷已完成對相關鋰電池隔離膜生產項目的項目備案
格隆匯7月1日丨恩捷股份(002812.SZ)公佈,近日,玉溪恩捷已完成對相關鋰電池隔離膜生產項目的項目備案,並取得玉溪市紅塔區發展和改革局下發的《投資項目備案證》(玉紅髮改產業基礎備案〔2022〕036號)。
項目名稱為年產16億平方米鋰電池隔離膜生產線建設項目,建設地點為雲南省玉溪市紅塔區紅塔工業園區蓮池地塊,主要建設內容:
項目總用地面積約485畝,總投資45億元,擬新建廠房20萬平方米,項目分兩期建設。其中:一期項目用地面積約240畝,計劃投資24億元,新建廠房11萬平方米,形成年產8億平方米鋰電池濕法隔膜的生產能力;二期項目用地面積約245畝,計劃投資21億元,新建廠房9萬平方米,形成年產8億平方米鋰電池濕法隔膜的生產能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.